Project Grant R01HL173488
Award Date
9/20/24
Completion Date
8/31/29
Dollars Obligated
$874K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90027, USA
Similar Awards
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), part of the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $176,515 to Children's Hospital Los Angeles (CHLA) to investigate the relationship between alveolar dead space and new or progressive multiple organ dysfunction syndrome (NPMODS) in critically ill children. The key objectives are to: Identify the association between alveolar dead space and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $200,502 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the molecular phenotypes and trajectories of acute respiratory distress syndrome (ARDS). The key objectives are to: Identify metabolite and protein drivers of ARDS evolution in patients with hyper-inflammatory and hypo-inflammatory ARDS...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $1,160,157 Project Grant to Liberandum Technologies, Inc. to develop and test a novel bidirectional synchronous flow-controlled ventilation system to improve oxygenation and ventilation in patients with acute respiratory distress syndrome (ARDS). The goal of this 1-year Phase I SBIR project is to create a ventilation system that can provide gentle...
This $782,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of TREK-1 potassium channels in acute respiratory distress syndrome (ARDS). The key objectives are to: 1) determine if ARDS decreases epithelial and endothelial TREK-1 levels, leading to cell membrane depolarization and calcium-dependent inflammation, and 2) evaluate if activating residual TREK-1...
This $186,408 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to evaluate CD14 as a potential therapeutic target for acute respiratory distress syndrome (ARDS). The project aims to: 1) determine the effects of the CD14-blocking antibody IC14 on cellular targets through blood leukocyte RNA sequencing analysis, 2) examine the relationship between the CD14-pathway biomarker presepsin...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $480,990 to the University of Illinois to investigate the role of aerocytes, a recently identified capillary endothelial cell population, in regulating alveolar epithelial regeneration following lung injury. The research aims to establish the central role of aerocytes and the signaling molecule R-spondin3 in guiding the...
This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
This Project Grant award for $1,147,992.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program aims to advance precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The primary objectives are to: Conduct deep phenotyping of human samples using advanced immunoprofiling and metagenomics analyses to better understand the functional immune responses and pathogen drivers underlying the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to support research on the genetic landscape of childhood interstitial and diffuse lung diseases (CHILD). The key objectives are to: 1) Define molecular profiles of 300 CHILD lung biopsy samples to identify patient clusters with similar underlying causes, 2) Analyze whole exome sequence data from 400 children with...